Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.39 |
| ▸ | HRH2 | P25021 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22282217 | 0.86 | HTR1A (0.43) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL20729452 | 0.85 | HTR1A (0.54) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL20729427 | 0.85 | HTR1A (0.54) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL22281966 | 0.85 | HTR1A (0.54) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL20656041 | 0.84 | SLC6A2 (0.35) | HTR1AHRH3KDM1A | |
| SCHEMBL27447200 | 0.80 | HTR1A (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL9917377 | 0.80 | HRH3 (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL21667892 | 0.80 | HRH3 (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL9917378 | 0.80 | HRH3 (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL22890922 | 0.79 | HTR1A (0.51) | HTR1AHRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HTR1A 4040/4885HRH3 3363/4885HRH2 3574/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | HTR1A 4040/4885HRH3 3363/4885HRH2 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.